Search Within

Lindsay Van Alstine

Formats
  1. Meeting Abstract (5)
  2. Journal Article (2)
Groups
  1. Biostatistics Service (7)
  2. Department of Medicine (7)
  3. Epidemiology and Biostatistics (7)
  4. Genitourinary Oncology Service (7)
  5. Solid Tumor Oncology Division (7)
  6. Survivorship Research (7)

More Groups

People
  1. Darren Feldman (7)
  2. George Bosl (7)
  3. Sujata Patil (7)
  4. Joel Sheinfeld (6)
  5. Robert Motzer (6)
  6. Amanda Hughes (5)

More People

Years
  1. 2015 (1)
  2. 2014 (2)
  3. 2013 (3)
  4. 2012 (1)
Publications
  1. Journal of Clinical Oncology (4)
  2. Biology of Blood and Marrow Transplantation (1)
  3. Clinical Cancer Research (1)
  4. Clinical Genitourinary Cancer (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Elsevier Inc. (2)
  3. American Association for Cancer Research (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/II trial of paclitaxel with ifosfamide followed by high-dose paclitaxel, ifosfamide, and carboplatin (TI-TIC) with autologous stem cell reinfusion for salvage treatment of germ cell tumors
    Journal Article

    Feldman, D. R.; Glezerman, I.; Patil, S.; Van Alstine, L.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M.; Reich, L.; more...
    Clinical Genitourinary Cancer (2015)

    Fulltext@MSK | Save
  • Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors
    Journal Article

    Feldman, D. R.; Iyer, G.; Van Alstine, L.; Patil, S.; Al-Ahmadie, H.; Reuter, V. E.; Bosl, G. J.; Chaganti, R. S.; Solit, D. B.
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • Phase I/II study of paclitaxel plus ifosfamide followed by high-dose paclitaxel, ifosfamide, and carboplatin with autologous stem cell reinfusion for salvage treatment of germ cell tumors
    Meeting Abstract

    Feldman, D. R.; Glezerman, I.; Patil, S.; Van Alstine, L.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M.; Reich, L.; more...
    Biology of Blood and Marrow Transplantation (2014)

    Fulltext@MSK | Save
  • Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Dorff, T. B.; Patil, S.; Van Alstine, L. J.; Momen, L.; Carousso, M.; Hughes, A.; Snively-Solomon, J.; Ketchens, C.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT)
    Meeting Abstract

    Jia, X.; Feldman, D. R.; Glezerman, I.; Van Alstine, L. J.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M. S.; Reich, L.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Dorff, T. B.; Patil, S.; Van Alstine, L. J.; Momen, L.; Carousso, M.; Hughes, A.; Snively-Solomon, J.; Ketchens, C.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts)
    Meeting Abstract

    Feldman, D. R.; Voss, M. H.; Jia, X.; Van Alstine, L. J.; Patil, S.; Fischer, P.; Sheinfeld, J.; Bosl, G. J.; Motzer, R. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save